Heska (HSKA) Upgraded at Sidoti

Heska (NASDAQ:HSKA) was upgraded by research analysts at Sidoti from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat reports. The firm currently has a $94.00 target price on the medical research company’s stock. Sidoti’s price target would suggest a potential upside of 35.80% from the company’s current price.

Other research analysts also recently issued research reports about the stock. B. Riley reaffirmed a “hold” rating and issued a $96.50 price target on shares of Heska in a research note on Friday, October 27th. BidaskClub downgraded shares of Heska from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a research note on Monday, December 4th. ValuEngine downgraded shares of Heska from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of Heska from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $110.08.

Heska (NASDAQ:HSKA) opened at $69.22 on Monday. The company has a market cap of $500.19, a PE ratio of 36.43, a P/E/G ratio of 1.88 and a beta of 0.67. Heska has a 12 month low of $68.84 and a 12 month high of $115.00.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total transaction of $681,957.64. Following the transaction, the insider now owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its position in Heska by 5.7% during the 2nd quarter. Northern Trust Corp now owns 120,060 shares of the medical research company’s stock valued at $12,255,000 after purchasing an additional 6,517 shares during the period. Vanguard Group Inc. increased its position in Heska by 31.7% during the 2nd quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after purchasing an additional 111,232 shares during the period. Bank of New York Mellon Corp increased its position in Heska by 3.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 100,278 shares of the medical research company’s stock valued at $8,834,000 after purchasing an additional 3,610 shares during the period. Schwab Charles Investment Management Inc. increased its position in Heska by 194.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 31,215 shares of the medical research company’s stock valued at $2,750,000 after purchasing an additional 20,624 shares during the period. Finally, Atlantic Trust Group LLC purchased a new position in Heska during the 3rd quarter valued at about $16,059,000. 80.13% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Heska (HSKA) Upgraded at Sidoti” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/02/07/heska-hska-upgraded-at-sidoti.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply